ArticleHepatology international2025
Outcomes of pediatric living donor liver transplantation using steatotic grafts: expanding the donor pool for rising MASLD prevalence.
Article in Hepatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Donor steatosis in the metabolic dysfunction-associated steatotic liver disease era: a retrospective analysis of challenges and outcomes in living donor liver transplantation.Clinical transplantation and research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundPediatric living donor liver transplantation (PLDLT) is a life-saving option for children with end-stage liver diseases. However, the growing prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) raises concerns regarding the use of steatotic donor grafts, particularly in vulnerable pediatric populations.
methodsThis study retrospectively investigated the impact of steatotic liver grafts on post-transplant outcomes in PLDLT recipients. 905 PLDLT recipients at Renji Hospital, Shanghai Jiao Tong University School of Medicine, from January 2019 to December 2021 were screened using computed tomography (CT) liver/spleen ratio and classified into three groups according to the degree of steatosis. This study evaluated early liver function, post-transplant complications, and long-term graft and patient survival.
resultsRecipients in the moderate-to-severe group exhibited higher incidence of rejection. However, there were no significant differences in early liver function and the 1-year and 3-year graft and patient survival among three groups.
conclusionsThe use of steatotic livers in PLDLT can be considered a viable option, with careful donor selection and vigilant postoperative management. These findings highlight the potential of MASLD as an expansion of the donor pool owing to its rising incidence and offer new insights into optimizing pediatric transplant outcomes while addressing the scarcity of suitable donor organs.
Indexed as
Identifiers
40679706What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.